Kura Oncology, Inc. - Common Stock (NQ:KURA)

10.53 -0.09 (-0.85%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026? ↗

August 25, 2026

Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

KOMZIFTI revenue surged 57% as new patient starts climbed 35%.

Via The Motley Fool

Topics Earnings

Kura Oncology Q2 Earnings Call Highlights ↗

August 12, 2026

Kura Oncology (NASDAQ:KURA) reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said...

Via MarketBeat

Topics Earnings

Kura Oncology (NASDAQ:KURA) Slips After Q1 Earnings Miss ↗

May 12, 2026

Via Chartmill

KURA ONCOLOGY INC (NASDAQ:KURA) Posts Q4 Revenue Beat but EPS Miss, Stock Falls in Pre-Market ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement ↗

October 24, 2025

Via Stocktwits

Kura Oncology Reports 50% Response Rate in RCC Combination Study ↗

July 27, 2026

Kura Oncology (NASDAQ:KURA) presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma...

Via MarketBeat

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript ↗

July 02, 2026

Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For...

Via Benzinga

Topics Earnings

Kura Oncology Q1 Earnings Call Highlights ↗

May 12, 2026

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad...

Via MarketBeat

Topics Earnings

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

May 12, 2026

From Kura Oncology, Inc.

Via GlobeNewswire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Uncovering Potential: Kura Oncology's Earnings Preview ↗

April 30, 2025

Via Benzinga

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

April 17, 2026

From Kura Oncology, Inc.

Via GlobeNewswire

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

January 11, 2026

From Kura Oncology, Inc.

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill ↗

November 14, 2025

Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.

Via Benzinga

Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients ↗

November 14, 2025

The FDA approved KOMZIFTI, a once-daily oral therapy for relapsed or refractory NPM1-mutated AML.

Via Stocktwits

Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025

November 05, 2025

The financial markets as of November 5, 2025, present a compelling dichotomy with the technology and pharmaceutical sectors charting distinct yet largely positive courses. While technology continues...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss ↗

November 04, 2025

Kura Oncology reported a Q3 2025 revenue miss but a narrower loss. Investors focus on the upcoming FDA decision for its lead drug, ziftomenib, a key catalyst.

Via Chartmill

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial ↗

October 24, 2025

Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.

Via Benzinga

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant...

Via MarketMinute

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 09, 2025

Via Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Via Benzinga

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 04, 2025

Via Benzinga

Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday ↗

August 15, 2025

Via Benzinga

Kura (KURA) Revenue Drops 61% ↗

August 07, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.